CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 91 enrolled
Drug / intervention
SURF-201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04324359
NCT04324359Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Double-Masked Study To Compare The Ocular Safety, Tolerability, And Efficacy Of A Topical 0.2% Ophthalmic Corticosteroid Solution (SURF-201) To Vehicle In Cataract Surgery Subjects

Surface Ophthalmics, Inc.·interventional·Posted Mar 27, 2020·Updated Jan 15, 2025

In Brief

A Phase 2 clinical trial evaluating SURF-201 and Placebo for Post-surgical Ocular Inflammation and Post-surgical Ocular Pain. Completed, enrolled 91 participants across 10 sites.

Detailed Summary

SURF-201 is being studied for the treatment of eye inflammation and pain in people who are undergoing cataract surgery. SURF-201 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop. The purpose of this research study is to see how well SURF-201 works and what side effects there are, and to compare it with Vehicle (placebo). This study will involve about 80 study participants at several different research sites in the United States.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-surgical Ocular Inflammation, Post-surgical Ocular Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedMar 27, 2020
Enrollment StartMar 3, 2020
Primary CompletionNov 3, 2020
Study CompletionNov 20, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.3 years ago

Interventions

SURF-201drug

One drop twice daily (BID) in the study eye for 16 days.

Placebodrug

One drop twice daily (BID) in the study eye for 16 days.